Dr. Reddy's Laboratories Limited·Healthcare

India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices up to 70% as analysts weigh global market disruption risks.

Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

Bessemer Group Inc. raised its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 30.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,350,988 shares of the company's stock after buying an additional 318,621 shares during the

Dr. Reddy's Laboratories (NYSE: RDY) reported a "resilient performance" in its fiscal third quarter of FY26, with revenue growth and steady profitability despite what management described as product-specific headwinds, led by lower lenalidomide sales and continued pricing pressure in U.S. and European generics. On the company's earnings call, Chief Financial Officer M.V. Narasimham (MVN) said consolidated

RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Healthcare
Drug Manufacturers - Specialty & Generic
27,048
2001-04-11
0.30